Quality Systems No Longer Theoretical as Industry Begins Implementing Concepts
Alignment of reality with ICH quality systems theory is under way. Industry is developing, promoting and implementing global solutions through ISPE's new PQLI process, with the involvement of regional regulators. Conformia's new, more complex mock P2 could kindle more QbD. Genentech's approach to QbD described in detail. Quality systems seen as an option you can't refuse. Lessons from the device sector. Why Lilly switched to quality systems and how it benefited. How Abbott prepares for the future with management reviews. What Amgen did to correct its CAPA process - and save millions of dollars along the way
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.